Marinomed Biotech AG secures licensure with leading Consumer Health Care
player for the distribution of Carragelose® products in Europe

EQS-News: Marinomed Biotech AG / Key word(s): Contract
Marinomed Biotech AG secures licensure with leading Consumer Health Care
player for the distribution of Carragelose® products in Europe

14.06.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Marinomed Biotech AG secures licensure with leading Consumer Health Care
player for the distribution of Carragelose® products in Europe

  * Marinomed signs an additional licensing agreement with an existing
    partner for the distribution and marketing of Carragelose® products in
    Europe and selected other countries

* Marinomed eligible to receive milestone payments

Korneuburg, Austria, 14 June 2024 - Marinomed Biotech AG (VSE:MARI) expands
its license regarding the distribution of Marinomed's Carragelose products
with an existing partner and leading Consumer Health Care market player. The
agreement provides for the marketing and distribution of Carragelose
products in several EU-countries and some non-EU countries pending any
required regulatory approvals. Under the terms of the agreement and
depending on the achievement of specified regulatory and commercial targets,
Marinomed is eligible to receive milestone payments.

"Broadening our license with a leading Consumer Health Company is a huge
success and validation of our Carragelose product line", Andreas Grassauer,
CEO of Marinomed, comments. "Expanding to additional countries is another
significant step for our business, and we are looking forward to realizing
the full potential of our products."

About Carragelose®

Carragelose® is a sulfated polymer from red seaweed and a unique, broadly
active virus- and allergen-blocking compound. It is known as a gentle,
effective, and safe prevention and treatment of various viral respiratory
infections. Several clinical and preclinical studies have shown that
Carragelose® forms a protective layer on the mucosa that prevents viruses
from infecting cells. Laboratory and clinical data have demonstrated that
Carragelose® can also inhibit the spreading of SARS-CoV-2. (1), (2)
Marinomed is the holder of the IP rights and has licensed Carragelose® for
marketing in Europe, North America, Australia, and parts of Asia and Latin
America. Marinomed's portfolio of Carragelose®-containing nasal sprays and
oral products can be accessed at
https://www.carragelose.com/en/portfolio/launched-products, scientific
publications on Carragelose® at https://www.carragelose.com/en/publications.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline and globally marketed therapeutics. The Company
develops innovative patent-protected products in the therapeutic areas
immunology and virology based on the platform Marinosolv® and the
virus-blocking activity of Carragelose®. The Marinosolv® technology improves
the solubility and bioavailability of hardly soluble compounds and is used
to develop new therapeutics for autoreactive immune disorders. The virology
segment includes Carragelose®-based over-the-counter (OTC) products to
prevent and treat respiratory viral infections that are partnered in more
than 40 countries. The Company is headquartered in Korneuburg, Austria, and
is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.

For further inquiries contact:

            Marinomed Biotech AG           International Media Contact
          PR & IR: Lucia Ziegler    Metrum Communications: Eva Ruppnig
           T: +43 2262 90300 158                    T: +43 664 4065744
     E-Mail: (1)pr@marinomed.com        E-Mail: (1)marinomed@metrum.at
     E-Mail: (2)ir@marinomed.com

                                         1. mailto:marinomed@metrum.at
      1. mailto:pr@marinomed.com
      2. mailto:ir@marinomed.com

Disclaimer

This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are subject
to risks, uncertainties and assumptions that could cause actual results,
performance or events to differ materially from those described in, or
expressed or implied by, such statements. The current views, expectations
and projections of the management of Marinomed Biotech AG may be identified
by the context of such statements or words such as "anticipate," "believe",
"estimate", "expect", "intend", "plan", "project" and "target".
Forward-looking statements are only valid as of the date they are made and
Marinomed Biotech AG does not assume any obligation to update, review or
revise any forward-looking statements contained in this press release
whether as a result of new information, future developments or otherwise.
Marinomed, Marinosolv® and Carragelose® are registered trademarks of
Marinomed Biotech AG. These trademarks may be owned or licensed in select
locations only.

(1)
https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM

(2)
https://www.marinomed.com/en/news/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1


---------------------------------------------------------------------------

14.06.2024 CET/CEST This Corporate News was distributed by EQS Group AG.
www.eqs.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Marinomed Biotech AG
                   Hovengasse 25
                   2100 Korneuburg
                   Austria
   Phone:          +43 2262 90300
   E-mail:         office@marinomed.com
   Internet:       www.marinomed.com
   ISIN:           ATMARINOMED6
   WKN:            A2N9MM
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Frankfurt, Munich, Stuttgart, Tradegate Exchange;
                   Vienna Stock Exchange (Official Market)
   EQS News ID:    1925017

End of News EQS News Service
---------------------------------------------------------------------------

1925017 14.06.2024 CET/CEST